Baker Botts L.L.P. advises pharma and medical device companies on IP, corporate matters, and antitrust investigations. Its IP practice covers strategy counselling, prosecution, due diligence, and litigation. The firm also handles corporate transactions such as M&A, financing, joint ventures, and licensing and collaboration agreements, with New York’s Avner Bengera being a prominent figure in this space. The practice is led by New York-based Steve Lendaris, who advises clients on a wide range of biotech-related IP matters. Also in this office, Carolyn Pirraglia – who was promoted to partner in March 2024 – focuses on patent prosecution and counseling.
Legal 500 Editorial commentary
Key clients
- Alga Biosciences
- AmplifyBio
- Antipodean Pharmaceuticals, Inc. / MitoQ Ltd
- Assertio Holdings, Inc.
- Canopy Growth Corporation
- Cipla Ltd.
- Columbia University
- Cytiva Life Sciences
- Editas Medicine
- Eikon Therapeutics, Inc.
Work highlights
Handles a variety of intellectual property diligence and prosecution matters for Oxford Nanopore Technologies.
Represents UnitedHealth Group Incorporated broadly in its M&A activities and reviews potential acquisitions.
Lawyers
Practice head
Steve Lendaris
Other key lawyers
Avner Bengera
Carolyn Pirraglia
Rachael Lamkin
Steve Mann
Michael Torosian